Dr. Martens (LON:DOCS) Announces Quarterly Earnings Results

Key Points

• Revenue fell 9.2% year over year to £292.4 million, while adjusted EBIT swung to a £2.2 million loss. Weakness was concentrated in Europe and direct-to-consumer sales, with boot sales down 20% amid hot weather and pressure on core styles.
• Cost controls helped cushion the downturn: comparable gross margin increased 80 basis points to 65.4%, supported by prior cost actions. Management expects margins to remain resilient, though some benefits may fade in the second half.
• The second half is pivotal: management expects boots to remain a headwind for the rest of FY 2027 and said core boot styles are still under pressure. Debt was broadly flat at £158.9 million, with covenant net debt to EBITDA of 2.2 times.

Dr. Martens (LON:DOCS - Get Free Report) posted its quarterly earnings data on Thursday. The company reported GBX (1) earnings per share (EPS) for the quarter, Digital Look Earnings reports. The company had revenue of £290.40 million for the quarter. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%.

Here are the key takeaways from Dr. Martens' conference call:

• Revenue fell 9.2% year over year to £292.4 million, and adjusted EBIT swung to a £2.2 million loss from a £3.1 million profit. The decline was concentrated in Europe and DTC, with boots sales down 20% amid unusually hot weather and ongoing pressure on core styles.
• Margin and cost discipline cushioned the sales decline: gross margin rose 80 basis points on a comparable basis to 65.4%, while operating costs benefited from prior cost actions. Management said margin should remain resilient, though some first-half benefits may ease in the second half.
• Debt remained broadly flat year over year at £158.9 million, and covenant net debt to EBITDA was 2.2 times versus a 3.0-times limit. Cash generation was seasonally negative by £66.2 million as the company built working capital ahead of peak trading.
• The company reported encouraging early responses to its With Bouncing Soles campaign, upgraded Brand Centres, and new Spring/Summer sandals range. Management cautioned that the campaign and store results are still early, and the new e-commerce platform has required time to bed in.
• Second-half performance is pivotal: management expects boots to remain a headwind for the rest of FY 2027, with core boot styles still under pressure, and said the business is focused on the key trading weeks ahead. Its full-price mix priorities in the U.K. and DACH are weighted to the second half.

Dr. Martens Price Performance

Shares of LON:DOCS traded down GBX 10.90 during trading on Thursday, reaching GBX 54.10. The stock had a trading volume of 121,855,430 shares, compared to its average volume of 6,573,813. Dr. Martens has a 52 week low of GBX 52.10 and a 52 week high of GBX 90. The business's 50-day moving average price is GBX 67.13 and its 200 day moving average price is GBX 69.53. The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13. The stock has a market capitalization of £517.88 million, a PE ratio of 22.54, a P/E/G ratio of 6.40 and a beta of 0.26.

Insider Buying and Selling

In related news, insider Ije Nwokori sold 209,160 shares of the firm's stock in a transaction on Friday, October 16th. The stock was sold at an average price of GBX 69, for a total transaction of £144,320.40. In the last 90 days, insiders purchased 927 shares of company stock worth $59,965. 2.97% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank reissued a "buy" rating and issued a GBX 110 target price on shares of Dr. Martens in a report on Friday, October 9th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of GBX 105.

Dr. Martens Company Profile

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, "Docs" or "DM's" were later adopted by musicians and subcultural pioneers who took them from the street to the global stage. Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.